ETS fusions were identified in 5 of 15 patients, with the remaining patients falling into the Other category in The Cancer Genome Atlas.24 Although we did observe enrichment of specific genomic drivers with treatment in individual patients (for example, an RB1 loss of heterozygosity event in NAT02), there was no consistent association between known drivers and tumor response, and in general, post-treatment samples had fewer detected somatic aberrations. The gene discussed is RB1; the disease is neoplasm.